Novel pyridine-containing azacrownethers for the chelation of therapeutic bismuth radioisotopes: Complexation study, radiolabeling, serum stability and biodistribution

Nowadays alpha-emitting radionuclides are the most perspective for target alpha therapy and 213Bi (T1/2  = 46 min) is one of the intensively studied for purpose. Despite the predominant decay by β-emission (98%) and only 2% by α-emission for 213Bi the presence of pure α-emitting 213Po and β-emitting 209Tl and 209Pb among its short-lived daughter radionuclides leads to its high therapeutic ef ficacy. The latter has already been demonstrated upon treatment of glioma, glioblastoma [1,2], neuroendocrine tumors [3] and prostate cancer [4].
Source: Nuclear Medicine and Biology - Category: Nuclear Medicine Authors: Source Type: research